Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
NOT YET RECRUITING
NCT07080619
PHASE2
SC-101 in Subjects With Advanced NECTIN4-Amplified Cancers
Sponsor: Tianjin ConjuStar Biologics Co., Ltd.
View on ClinicalTrials.gov
Summary
This study is an open-label, multicenter Phase IIa trial to evaluate the efficacy and safety of SC-101 monotherapy in patients with locally advanced or metastatic malignant tumors who are positive for NECTIN4 gene amplification.
Official title: A Phase IIa Clinical Study to Assess the Efficacy and Safety of SC-101 in Patients With Advanced Malignant Tumors Positive for NECTIN4 Gene Amplification
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
120
Start Date
2025-09-20
Completion Date
2027-12-30
Last Updated
2025-09-11
Healthy Volunteers
No
Interventions
DRUG
SC-101
Receive 7.5 mg/m² of SC-101 intravenously once weekly (QW).